Navigating the Pandemic Response Life Cycle: Molecular Diagnostics and Immunoassays in the Context of COVID-19 Management

User-centered visual explorer of in-process comparison in spatiotemporal space

Abstract

We propose a user-centered visual explorer (UcVE) for progressive comparing multiple visualization units in spatiotemporal space. We create unique unit visualization with the customizable aggregated view based on the visual metaphor of flower bursts. Each visualization unit is encoded with the abstraction of spatiotemporal properties. To reduce user cognition load, UcVE allows users to visualize, save, and track in-the-process exploration results. In coordination of storage sequence and block tracking views, UcVE can facilitate comparison with multiple visualization units concurrently, selected from historical and current exploration results. UcVE offers a flexible geo-based layout, with aggregation functions and temporal views of the timeline with categorized events, to maximize the user's exploration capabilities. Finally, we demonstrate the usefulness by using COVID-19 datasets, case studies with different user scenarios, and expert feedback.

Graphical abstract

A comprehensive review on variants of SARS-CoVs-2: Challenges, solutions and open issues

SARS-CoV-2 is an infected disease caused by one of the variants of Coronavirus which emerged in December 2019. It is declared a pandemic by WHO in March 2020. COVID-19 outbreak has put the world on a halt and is a major threat to the public health system. It has shattered the world with its effects on different areas as the pandemic hit the world in a number of waves with different variants and mutations. Each variant and mutation have different transmission and infection rates in the human population. More than 609 million people have tested positive and more than 6.5 million people have died due to this disease as per 14th September 2022. Despite of numerous efforts, precautions and vaccination the infection has grown rapidly in the world. In this paper, we aim to give a holistic overview of COVID-19 its variants, game theory perspective, effects on the different social and economic areas, diagnostic advancements, treatment methods. A taxonomy is made for the proper insight of the work demonstrated in the paper. Finally, we discuss the open issues associated with COVID-19 in different fields and futuristic research trends in the area. The main aim of the paper is to provide comprehensive literature that covers all the areas and provide an expert understanding of the COVID-19 techniques and potentially be further utilized to combat the outbreak of COVID-19.

A precise review on NAATs-based diagnostic assays for COVID-19: A motion in fast POC molecular tests

BACKGROUND

Diagnosis is one of the main strategies to deal with infectious and deadly diseases such as coronavirus disease 2019 (COVID-19). The global pandemic of COVID-19 has led to an immediate need to expand rapid diagnostic techniques. New isothermal-based methods are being developed for COVID-19 detection aiming to resolve the limitations related to the reverse transcription-quantitative polymerase chain reaction (RT-qPCR) method through immediate samples processing and minimizing false-negative or ambiguous results. Advances in nucleic acid amplification techniques (NAATs) can provide affordable and easy-to-use diagnostic platforms with high sensitivity and specificity in order to be available to the public as approved commercial kits.

AIMS

The development of point-of-care (POC) testing can assist in rapid clinical decision-making and mitigate burdens on health care facilities. Finally, we discussed the different diagnostic methods based on NAATs for COVID-19 in detail. Comparative parameters are addressed for all assays and Emergency Use Authorizations (EUA)-approved commercial tests are cited.

CONCLUSIONS

Isothermal-coupled methods and LAMP-based molecular methods have been suggested as suitable portable tests with high diagnostic speed for use in POC testing.

Non-Coding RNAs in Rheumatoid Arthritis: Implications for Biomarker Discovery

Recent advances in gene expression analysis techniques and increased access to technologies such as microarrays, qPCR arrays, and next-generation sequencing, in the last decade, have led to increased awareness of the complexity of the inflammatory responses that lead to pathology. This finding is also the case for rheumatic diseases, importantly and specifically, rheumatoid arthritis (RA). The coincidence in major genetic and epigenetic regulatory events leading to RA’s inflammatory state is now well-recognized. Research groups have characterized the gene expression profile of early RA patients and identified a group of miRNAs that is particularly abundant in the early stages of the disease and miRNAs associated with treatment responses. In this perspective, we summarize the current state of RNA-based biomarker discovery and the context of technology adoption/implementation due to the COVID-19 pandemic. These advances have great potential for clinical application and could provide preclinical disease detection, follow-up, treatment targets, and biomarkers for treatment response monitoring.

A Comprehensive Overview of the Newly Emerged COVID-19 Pandemic: Features, Origin, Genomics, Epidemiology, Treatment, and Prevention

The coronavirus disease 2019 (COVID-19), a life-threatening pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has resulted in massive destruction and is still continuously adding to its death toll. The advent of this global outbreak has not yet been confirmed; however, investigation for suitable prophylaxis against this lethal virus is being carried out by experts all around the globe. The SARS-CoV-2 belongs to the Coronaviridae superfamily, like the other previously occurring human coronavirus variants. To better understand a new virus variant, such as the SARS-CoV-2 delta variant, it is vital to investigate previous virus strains, including their genomic composition and functionality. Our study aimed at addressing the basic overview of the virus’ profile that may provide the scientific community with evidence-based insights into COVID-19. Therefore, this study accomplished a comprehensive literature review that includes the virus’ origin, classification, structure, life cycle, genome, mutation, epidemiology, and subsequent essential factors associated with host–virus interaction. Moreover, we summarized the considerable diagnostic measures, treatment options, including multiple therapeutic approaches, and prevention, as well as future directions that may reduce the impact and misery caused by this devastating pandemic. The observations and data provided here have been screened and accumulated through extensive literature study, hence this study will help the scientific community properly understand this new virus and provide further leads for therapeutic interventions.

Towards Fully Integrated Portable Sensing Devices for COVID-19 and Future Global Hazards: Recent Advances, Challenges, and Prospects

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, this fatal disease has been the leading cause of the death of more than 3.9 million people around the world. This tragedy taught us that we should be well-prepared to control the spread of such infectious diseases and prevent future hazards. As a consequence, this pandemic has drawn the attention of many researchers to the development of portable platforms with short hands-on and turnaround time suitable for batch production in urgent pandemic situations such as that of COVID-19. Two main groups of diagnostic assays have been reported for the detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) including nucleic acid-based and protein-based assays. The main focus of this paper is on the latter, which requires a shorter time duration, less skilled technicians, and faces lower contamination. Furthermore, this paper gives an overview of the complementary metal-oxide-semiconductor (CMOS) biosensors, which are potentially useful for implementing point-of-care (PoC) platforms based on such assays. CMOS technology, as a predominant technology for the fabrication of integrated circuits, is a promising candidate for the development of PoC devices by offering the advantages of reliability, accessibility, scalability, low power consumption, and distinct cost.

Correlation-Based Analysis of COVID-19 Virus Genome Versus Other Fatal Virus Genomes

Virus attacks have had devastating effects on mankind. The prominent viruses such as Ebola virus (2012), SARS-CoV or Severe acute respiratory syndrome, Middle East respiratory syndrome-related coronavirus called as the MERS (EMC/2012), Spanish flu (H1N1 virus-1918) and the most recent COVID-19(SARS-CoV-2) are the ones that have created a difficult situation for the survival of the human race. Currently, throughout the world, a global pandemic situation has put economy, livelihood and human existence in a very pathetic situation. Most of the above-mentioned viruses exhibit some similar characteristics and genetic pattern. Analysing such characteristics and genetic pattern can help the researchers to get a deeper insight into the viruses and helps in finding appropriate medicine or cure. To address these issues, this paper proposes an experimental analysis of the above-mentioned viruses data using correlation methods. The virus data considered for the experimental analysis include the distribution of various amino acids, protein sequences, 3D modelling of viruses, pairwise alignment of proteins that comprise the DNA genome of the viruses. Furthermore, this comparative analysis can be used by the researchers and organizations like WHO(World Health Organization), computational biologists, genetic engineers to frame a layout for studying the DNA sequence distribution, percentage of GC (guanine-cytosine) protein which determines the heat stability of viruses. We have used the Biopython to illustrate the gene study of prominent viruses and have derived results and insights in the form of 3D modelling. The experimental results are more promising with an accuracy rate of 96% in overall virus relationship calculation.

COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development

In 2019, an unprecedented disease named coronavirus disease 2019 (COVID-19) emerged and spread across the globe. Although the rapid transmission of COVID-19 has resulted in thousands of deaths and severe lung damage, conclusive treatment is not available. However, three COVID-19 vaccines have been authorized, and two more will be approved soon, according to a World Health Organization report on December 12, 2020. Many COVID-19 patients show symptoms of acute lung injury that eventually leads to pulmonary fibrosis. Our aim in this article is to present the relationship between pulmonary fibrosis and COVID-19, with a focus on angiotensin converting enzyme-2. We also evaluate the radiological imaging methods computed tomography (CT) and chest X-ray (CXR) for visualization of patient lung condition. Moreover, we review possible therapeutics for COVID-19 using four categories: treatments related and unrelated to lung disease and treatments that have and have not entered clinical trials. Although many treatments have started clinical trials, they have some drawbacks, such as short-term and small-group testing, that need to be addressed as soon as possible.

Rapid point-of-care testing for COVID-19: quality of supportive information for lateral flow serology assays

OBJECTIVE

There is a lack of evidence addressing several important human factors questions pertaining to the quality of supportive information provided by commercial manufacturers that can affect the adoption and use of lateral flow serology assays in practice. We aimed to: (1) identify and assess the quality of information that commercial manufacturers provided for their point-of-care tests (POCTs) and (2) examine the implications of these findings on real-world settings.

DESIGN

We used a content analysis methodology in two stages to systematically, code and analyse textual data from documents of commercial manufacturers. A deductive approach was applied using a coding guide based on the validated Point-of-Care Key Evidence Tool (POCKET) multidimensional checklist. An inductive approach was used to identify new patterns or themes generated from our textual analysis.

SETTING

Publicly available supportive information documents by commercial manufacturers for lateral flow serology, were identified and gathered from online searches.

PARTICIPANTS

Supportive information documents retrieved from online searches over 3 months (March 2020 to June 2020).

RESULTS

A total of 79 POCTs were identified that met the study inclusion criteria. Using the POCKET coding guide, we found that the quality of information varied significantly between the manufacturers and was often lacking in detail. Our inductive approach further examined these topics and found that several statements were vague and that significant variations in the level of details existed between manufacturers.

CONCLUSIONS

This study revealed significant concerns surrounding the supportive information reported by manufacturers for lateral flow serology assays. Information transparency was poor and human factor issues were not properly addressed to mitigate the risk of improper device use, although it should be noted that the results of our study are limited by the data that manufactures were prepared to disclose. Overall, commercial manufacturers should improve the quality and value of information presented in their supporting documentation.

Symptom Tracking and Experimentation Platform for Covid-19 or Similar Infections

Remote symptom tracking is critical for the prevention of Covid-19 spread. The qualified medical staff working in the call centers of primary health care units have to take critical decisions often based on vague information about the patient condition. The congestion and the medical protocols that are constantly changing often lead to incorrect decisions. The proposed platform allows the remote assessment of symptoms and can be useful for patients, health institutes and researchers. It consists of mobile desktop applications and medical sensors connected to cloud infrastructure. The unique features offered by the proposed solution are: (a) dynamic adaptation of Medical Protocols (MP) is supported (for the definition of alert rules, sensor sampling strategy and questionnaire structure) covering different medical cases (pre- or post-hospitalization, vulnerable population, etc.), (b) anonymous medical data can be statistically processed in the context of the research about an infection such as Covid-19, (c) reliable diagnosis is supported since several factors are taken into consideration, (d) the platform can be used to drastically reduce the congestion in various healthcare units. For the demonstration of (b), new classification methods based on similarity metrics have been tested for cough sound classification with an accuracy in the order of 90%.

A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients

The COVID-19 pandemic affects more than 81 million people worldwide with over 1.7 million deaths. As the population returns to work, it is critical to develop tests that reliably detect SARS-CoV-2-specific antibodies. Here we present results from a multiplex serology test for assessing the antibody responses to COVID-19. In an initial large cohort, this test shows greater than 99% agreement with COVID-19 PCR test. In a second outpatient cohort consisting of adults and children in Colorado, the IgG responses are more robust in positive/symptomatic participants than in positive/asymptomatic participants, the IgM responses in symptomatic participants are transient and largely fall below the detection limit 30 days after symptom onset, and the levels of IgA against SARS-CoV-2 receptor binding domain are significantly increased in participants with moderate-to-severe symptoms compared to those with mild-to-moderate symptoms or asymptomatic individuals. Our results thus provide insight into serology profiling and the immune response to COVID-19.

Accurate computation: COVID-19 rRT-PCR positive test dataset using stages classification through textual big data mining with machine learning

In every field of life, advanced technology has become a rapid outcome, particularly in the medical field. The recent epidemic of the coronavirus disease 2019 (COVID-19) has promptly become outbreaks to identify early action from suspected cases at the primary stage over the risk prediction. It is overbearing to progress a control system that will locate the coronavirus. At present, the confirmation of COVID-19 infection by the ideal standard test of reverse transcription-polymerase chain reaction (rRT-PCR) by the extension of RNA viral, although it presents identified from deficiencies of long reversal time to generate results in 2-4 h of corona with a necessity of certified laboratories. In this proposed system, a machine learning (ML) algorithm is used to classify the textual clinical report into four classes by using the textual data mining method. The algorithm of the ensemble ML classifier has performed feature extraction using the advanced techniques of term frequency-inverse document frequency (TF/IDF) which is an effective information retrieval technique from the corona dataset. Humans get infected by coronaviruses in three ways: first, mild respiratory disease which is globally pandemic, and human coronaviruses are caused by HCoV-NL63, HCoV-OC43, HCoV-HKU1, and HCoV-229E; second, the zoonotic Middle East respiratory syndrome coronavirus (MERS-CoV); and finally, higher case casualty rate defined as severe acute respiratory syndrome coronavirus (SARS-CoV). By using the machine learning techniques, the three-way COVID-19 stages are classified by the extraction of the feature using the data retrieval process. The TF/IDF is used to measure and evaluate statistically the text data mining of COVID-19 patient's record list for classification and prediction of the coronavirus. This study established the feasibility of techniques to analyze blood tests and machine learning as an alternative to rRT-PCR for detecting the category of COVID-19-positive patients.

The potential of electrochemistry for the detection of coronavirus-induced infections

Human coronaviruses (HCoV) are no stranger to the global environment. The etiology of previous outbreaks with reported symptoms of respiratory tract infections was attributed to different coronavirus strains, with the latest global pandemic in 2019 also belonging to the coronavirus family. Timely detection, effective therapeutics and future prevention are stake key holders in the management of coronavirus-induced infections. Apart from the gold standard clinical diagnostics, electrochemical techniques have also demonstrated their great potentials in the detection of different viruses and their correlated antibodies and antigens, showing high sensitivities and selectivities, and faster times for the analysis. This article aims to critically review the multifaceted electrochemical approaches, not only in the development of point-of-care portable devices but also as alternative detection strategies that can be coupled with traditional methods for the detection of various strains of coronaviruses.

Monolithic 3D micromixer with an impeller for glass microfluidic systems

The performance of micromixers, namely their mixing efficiency and throughput, is a critical component in increasing the overall efficiency of microfluidic systems (e.g., lab-on-a-chip and μ-TAS). Most previously reported high-performance micromixers use active elements with some external power to induce turbulence, or contain long and complex fluidic channels with obstacles to increase diffusion. In this paper, we introduce a new type of 3D impeller micromixer built within a single fused silica substrate. The proposed device is composed of microchannels with three inlets and a tank, with a mixing impeller passively rotated by axial flow. The passive micromixer is directly fabricated inside a glass plate using a selective laser-induced etching technique. The mixing tank, with its rotating shaft and 3D pitched blade impeller, exists within a micro-cavity with a volume of only 0.28 mm3. A mixing efficiency of 99% is achieved in mixing experiments involving three dye colours over flow rates ranging from 1.5-30 mL min-1, with the same flow rates also applied to a sodium hydroxide-based bromothymol blue indicator and a hydrochloric acid chemical solution. To verify the reliable performance of the proposed device, we compare the mixing index with a general self-circulation-type chamber mixer to demonstrate the improved mixing efficiency achieved by rotating the impeller. No cracking or breakage of the device is observed under high inner pressures or when the maximum flow rate is applied to the mixer. The proposed microfluidic system based on a compact built-in 3D micromixer with an impeller opens the door to robust, highly efficient, and high-throughput glass-based platforms for micro-centrifuges, cell sorters, micro-turbines, and micro-pumps.

DFC, Medina E, Sinche F, Santiago Vispo N, Dahoumane SA, Alexis F. Biomedical Science to Tackle the COVID-19 Pandemic: Current Status and Future Perspectives

The coronavirus infectious disease (COVID-19) pandemic emerged at the end of 2019, and was caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which has resulted in an unprecedented health and economic crisis worldwide. One key aspect, compared to other recent pandemics, is the level of urgency, which has started a race for finding adequate answers. Solutions for efficient prevention approaches, rapid, reliable, and high throughput diagnostics, monitoring, and safe therapies are needed. Research across the world has been directed to fight against COVID-19. Biomedical science has been presented as a possible area for combating the SARS-CoV-2 virus due to the unique challenges raised by the pandemic, as reported by epidemiologists, immunologists, and medical doctors, including COVID-19's survival, symptoms, protein surface composition, and infection mechanisms. While the current knowledge about the SARS-CoV-2 virus is still limited, various (old and new) biomedical approaches have been developed and tested. Here, we review the current status and future perspectives of biomedical science in the context of COVID-19, including nanotechnology, prevention through vaccine engineering, diagnostic, monitoring, and therapy. This review is aimed at discussing the current impact of biomedical science in healthcare for the management of COVID-19, as well as some challenges to be addressed.

Fighting COVID-19: Integrated Micro- and Nanosystems for Viral Infection Diagnostics

The pandemic of coronavirus disease 2019 (COVID-19) highlights the importance of rapid and sensitive diagnostics of viral infection that enables the efficient tracing of cases and the implementation of public health measures for disease containment. The immediate actions from both academia and industry have led to the development of many COVID-19 diagnostic systems that have secured fast-track regulatory approvals and have been serving our healthcare frontlines since the early stage of the pandemic. On diagnostic technologies, many of these clinically validated systems have significantly benefited from the recent advances in micro- and nanotechnologies in terms of platform design, analytical method, and system integration and miniaturization. The continued development of new diagnostic platforms integrating micro- and nanocomponents will address some of the shortcomings we have witnessed in the existing COVID-19 diagnostic systems. This Perspective reviews the previous and ongoing research efforts on developing integrated micro- and nanosystems for nucleic acid-based virus detection, and highlights promising technologies that could provide better solutions for the diagnosis of COVID-19 and other viral infectious diseases. With the summary and outlook of this rapidly evolving research field, we hope to inspire more research and development activities to better prepare our society for future public health crises.

Scalable COVID-19 Detection Enabled by Lab-on-Chip Biosensors

Introduction

The emergence of a novel coronavirus, SARS-CoV-2, has highlighted the need for rapid, accurate, and point-of-care diagnostic testing. As of now, there is not enough testing capacity in the world to meet the stated testing targets, which are expected to skyrocket globally for broader testing during reopening

Aim

This review focuses on the development of lab-on-chip biosensing platforms for diagnosis of COVID-19 infection.

Results

We discuss advantages of utilizing lab-on-chip technologies in response to the current global pandemic, including their potential for low-cost, rapid sample-to-answer processing times, and ease of integration into a range of healthcare settings. We then highlight the development of magnetic, colorimetric, plasmonic, electrical, and lateral flow-based lab-on-chip technologies for the detection of SARS-CoV-2, in addition to other viruses. We focus on rapid, point-of-care technologies that can be deployed at scale, as such devices could be promising alternatives to the current gold standard of reverse transcription-polymerase chain reaction (RT-PCR) diagnostic testing.

Conclusion

This review is intended to provide an overview of the current state-of-the-field and serve as a resource for innovative development of new lab-on-chip assays for COVID-19 detection.